ScholarIQanswers from OpenAlex & ORCID
Carey K. Anders
ResearcherPublications, citations & collaboration network
Carey K. Anders is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Carey K. Anders have?
ScholarIQindexed works
Carey K. Anders has 518 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Carey K. Anders have?
ScholarIQcitation count
Carey K. Anders has 17,147 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Carey K. Anders?
ScholarIQh-index
Carey K. Anders has an h-index of 66 in OpenAlex.
What is the i10-index of Carey K. Anders?
ScholarIQi10-index
Carey K. Anders has an i10-index of 148 in OpenAlex.
What is the ORCID of Carey K. Anders?
ScholarIQorcid
The ORCID for Carey K. Anders is on the source record.
What is the OpenAlex record for Carey K. Anders?
ScholarIQopenalex
The OpenAlex for Carey K. Anders is on the source record.
What are the most-cited papers on Carey K. Anders?
ScholarIQmost cited works
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Nancy U. Lin, Virginia F. Borges, Vandana G. Abramson, Carey K. Anders, Philippe L. Bédard, Mafalda Oliveira, Erik Jakobsen, Thomas Bachelot, Shlomit Strulov Shachar, Volkmar Müller, Sofía Braga, François P. Duhoux, Richard Greil, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Gabriel N. Hortobágyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Maria Corinna Palanca-Wessels, Luke Walker, Wentao Feng, Eric P. Winer
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Rashmi K. Murthy, Elisavet Paplomata, Erika Hamilton, Sara A. Hurvitz, Sherene Loi, Alicia Okines, Vandana G. Abramson, Philippe L. Bédard, Mafalda Oliveira, Volkmar Müller, Amelia Zelnak, Michael P. DiGiovanna, Thomas Bachelot, A. Jo Chien, Ruth O’Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Karen A. Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P. Winer
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey, Donald A. Berry, Constance Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay N. Harris, David W. Ollila, Ian E. Krop, N. Lynn Henry, Douglas Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael D. Iglesia, Maggie C.U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, PierFranco Conte, Véronique Dièras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders